According to statistics, chronic myelogenous leukemia (CML) accounts for about 15% of the total quantity of leukemias and is characterized by a
significantly increased number of granulocytes in the blood [1]. CML is described by a 3-phase course of the disease, treatment in each subsequent phase
becomes more resistant to drugs. The development of the selective Bcr-Abl tyrosine kinase inhibitor Imatinib has improved the treatment of patients with CML, however, several patients do not tolerate, or develop resistance to Imatinib [2]. Therefore, the development of new approaches to the treatment of CML is an important task.